B cells play a major role in the pathophysiology of myasthenia gravis (MG) with their ability to produce disease specific, pathogenic antibodies. However, their status during disease development and follow-up stages of the disease in the peripheral blood may need further studies to determine useful markers. In this study, we aimed to detect B cell associated factors concerning immunosuppressive treatment in generalized non-thymomatous MG patients. Although CD19+ B cell distribution did not vary among disease subgroups, expressions of both CD38 and BAFFR were altered on B cells in MG patients under immunosuppressive therapy. Serum levels of BAFF were elevated in untreated MG patients as compared to treated MG patients and healthy controls. B cell activation factors may show profound alterations due to immunosuppression.

中文翻译：

---

抗体阳性重症肌无力患者外周B细胞标志物的治疗效果

B 细胞在重症肌无力 (MG) 的病理生理学中发挥重要作用，具有产生疾病特异性、致病性抗体的能力。然而，它们在疾病发展和外周血疾病随访阶段的状态可能需要进一步研究以确定有用的标志物。在本研究中，我们旨在检测与全身性非胸腺瘤性 MG 患者免疫抑制治疗相关的 B 细胞相关因素。尽管 CD19+ B 细胞分布在疾病亚组之间没有变化，但免疫抑制治疗下 MG 患者 B 细胞上 CD38 和 BAFFR 的表达都发生了改变。与接受治疗的 MG 患者和健康对照相比，未接受治疗的 MG 患者的血清 BAFF 水平升高。由于免疫抑制，B 细胞活化因子可能显示出深刻的改变。